Discover Valuable Insights and Strategies

The weight loss drug litigation landscape has exploded with cases involving GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. But there's a critical bottleneck preventing many firms from capitalizing on this lucrative area: the overwhelming complexity of plaintiff fact sheets (PFS).

In May 2023, I joined my mentor Dr. Ralph Horwitz and friend Abbey at a reading of Abraham Verghese’s The Covenant of Water—a full-circle moment rooted in Ralph’s decades-long friendship with Abraham and a reminder of how Parambil was named: to honor the power of lasting relationships, bold ideas, and the shared commitment to building something meaningful.

Parambil raised $2M to scale AI tools that boost litigation accuracy, speed, and scale across mass torts, PI, and defense.